SGMT vs. IMAB, RGLS, CRVO, SKYE, INCR, PDSB, CTMX, RPTX, MCRB, and ACET
Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include I-Mab (IMAB), Regulus Therapeutics (RGLS), CervoMed (CRVO), Skye Bioscience (SKYE), InterCure (INCR), PDS Biotechnology (PDSB), CytomX Therapeutics (CTMX), Repare Therapeutics (RPTX), Seres Therapeutics (MCRB), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
I-Mab (NASDAQ:IMAB) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.
In the previous week, Sagimet Biosciences had 13 more articles in the media than I-Mab. MarketBeat recorded 13 mentions for Sagimet Biosciences and 0 mentions for I-Mab. I-Mab's average media sentiment score of 0.43 beat Sagimet Biosciences' score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the news media.
I-Mab currently has a consensus target price of $12.25, indicating a potential upside of 600.00%. Sagimet Biosciences has a consensus target price of $38.80, indicating a potential upside of 739.83%. Given I-Mab's higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than I-Mab.
I-Mab received 42 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 62.92% of users gave I-Mab an outperform vote.
Sagimet Biosciences has lower revenue, but higher earnings than I-Mab.
38.4% of I-Mab shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 17.6% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Sagimet Biosciences' return on equity of 0.00% beat I-Mab's return on equity.
Summary
Sagimet Biosciences beats I-Mab on 8 of the 13 factors compared between the two stocks.
Get Sagimet Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sagimet Biosciences Competitors List
Related Companies and Tools
